Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Med
Main Authors: Solitano, Virginia, D’Amico, Ferdinando, Fiorino, Gionata, Paridaens, Kristine, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2020
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/
https://ncbi.nlm.nih.gov/pubmed/32911840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares